General
Preferred name
Oteseconazole
Synonyms
VT-1161 ()
Otesaconazole ()
Oteseconazol ()
Vivjoa ()
P&D ID
PD058275
CAS
1340593-59-0
Tags
available
drug
Approved by
FDA
First approval
2022
Drug indication
Onychomycosis
Tinea pedis
Vulvovaginal Candidiasis
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Oteseconazole (VT-1161) is a potent and orally active anti-fungal agent. Oteseconazole potently binds to and inhibits Candida albicans cytochrome P45051 (CYP51) activity (Kd ¡Ü39 nM), shows no obvious effect on human CYP51. Oteseconazole also can be used for the research of dermatophytes[1][2].
PRICE 379
DESCRIPTION Oteseconazole (VT-1161) is an orally active anti-fungal agent. Oteseconazole displays no obvious effect on human CYP51. It also potently binds to and inhibits Candida albicans CYP51 (Kd, <39 nM). (TargetMol Bioactive Compound Library)
Compound Sets
12
Cayman Chemical Bioactives
43577
ChEMBL Approved Drugs
CHEMBL3311228
ChEMBL Drugs
CHEMBL3311228
DrugBank
DB13055
DrugBank Approved Drugs
DB13055
DrugCentral
5510
DrugCentral Approved Drugs
5510
DrugMAP
DM7R145
MedChem Express Bioactive Compound Library
HY-17643
Pandemic Response Box
ReFrame library
TargetMol Bioactive Compound Library
T16412
External IDs
20
Properties
(calculated by RDKit )
Molecular Weight
527.12
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
4
cLogP
4.63
TPSA
85.95
Fraction CSP3
0.22
Chiral centers
1.0
Largest ring
6.0
QED
0.34
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Metabolism
Microbiology/virology
Anti-infection
Metabolic Enzyme/Protease
Target
Cytochrome P450
Fungal
Antifungal
CYP51
Source data